Publication Year

Lea IA, Chappell GA, Wikoff DS. 2021. Overall lack of genotoxic activity among five common low- and no-calorie sweeteners: A contemporary review of the collective evidence. Mutat Res Genet Toxicol Environ Mutagen 868–869:503389. doi: 10.1016/j.mrgentox.2021.503389. PMID: 34454695.

Wikoff D, Fitch S, Borghoff S. Case-study applications using evidence-based approaches to assess endocrine activity for risk assessment. Invited speaker (Wikoff):  61^st Annual Meeting (virtual) of the Society for Birth Defects Research & Prevention, June 2021.

Wikoff D. The [acceptable daily intake] for low- and no-calorie sweeteners: Origin, interpretation, and application. Invited speaker: Continuing education webinar, Institute for the Advancement of Food and Nutrition Sciences, July 2021.

Fitch SE, Payne LE, van de Ligt JLG, Doepker C, Handu D, Cohen SM, Anyangwe N, Wikoff D. 2021. Use of acceptable daily intake (ADI) as a health-based benchmark in nutrition research studies that consider the safety of low-calorie sweeteners (LCS): A systematic map. BMC Public Health 21(1):956, doi: 10.1186/s12889-021-10934-2.

Borghoff SJ, Fitch SE, Black MVB, McMullen PD, Andersen ME, Chappell GA. 2021. A systematic approach to evaluate plausible modes of [action] for mouse lung tumors in mice exposed to 4-methylimidozole. Regul Toxicol Pharmacol 124:104977; DOI: 10.1016/j.yrtph.2021.104977.

Whaley P, Blaauboer BJ, Brozek J, Cohen Hubal EA, Hair K, Kacew S, Knudsen TB, Kwiatkowski CF, Mellor DT, Olshan AF, Page MJ, Rooney AA, Radke E, Shamseer L, Tsaioun K, Tugwell P, Wikoff D, Woodruff TJ. 2021. Improving the quality of toxicology and environmental health systematic reviews: What journal editors can do. ALTEX [Internet].

Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124:104969, doi.org/10.1016/j.yrtph.2021.104969.

Ring C, Sipes NS, Hsieh JH, Carberry C, Koval LE, Klaren WD, Harris MA, Auerbach SS, Rager JE. 2021. Predictive modeling of biological responses in the rat liver using in vitro Tox21 bioactivity: Benefits from high throughput toxicokinetics. Comput Toxicol 18:100166; doi: 10.1016/j.comtox.2021.100166. PMID: 34013136.

de Vries RBM, Angrish M, Browne P, Brozek J, Rooney AA, Wikoff DS, Whaley P, Edwards SW, Morgan RL, Druwe IL, Hoffmann S, Hartung T, Thayer K, Avey MT, Beverly BEJ, Falavigna M, Gibbons C, Goyak K, Kraft A, Nampo F, Qaseem A, Sears M, Singh JA, Willett C, Yost EY, Schünemann H, Tsaioun K. 2021. Applying evidence-based methods to the development and use of adverse outcome pathways. ALTEX — Alternatives to Animal Experimentation, 38(2):336–347, doi: 10.14573/altex.2101211.

Dirven H, Vist GE, Bandhakavi S, Mehta J, Fitch SE, Pound P, Ram R, Kincaid B, Leenaars CHC, Chen M, Wright RA, Tsaioun K. 2021. Performance of preclinical models in predicting drug-induced liver injury in humans: A systematic review. Nature, Scientific Reports; open access.